New research indicates that patients who stop using new slimming jabs like Mounjaro or Wegovy can put back on reduced body mass at a significantly accelerated pace than those who stop traditional lifestyle programs.
Findings released in a prominent medical journal shows that while overweight people can lose substantial amounts of their body weight while undergoing treatment, the mass is regained at an average rate of 0.8 kg per month once they quit.
"Users purchasing such medications need to be aware of the potential of quick rebound weight gain when the therapy is stopped," cautioned expert Dr. Susan Jebb.
This pace of regain means a reversion to pre-treatment mass within about 18 months.
Weighing Therapies
The analysis, which looked at 37 of studies involving over 9,000 of participants, contrasted the outcomes of GLP-1 agonists with older methods.
The team emphasize that individuals who lose weight through lifestyle changes alone typically experience a less rapid weight regain—around 100 grams monthly—after stopping.
Explaining the Fast Rebound
Doctors propose the mechanism of the drugs explains the amplified rebound.
These medications mimic a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production could lead to the body to produce less of its own natural GLP-1, and could lessen responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this GLP-1 'fix' results in hunger is unsuppressed, making overeating far more likely."
A Chronic Disease?
Health authorities suggest the injections for people with weight-linked health risks, alongside recommended diet and exercise modifications.
Professionals argue that, due to the high risk of relapse, the therapy might need to be long-term.
This view is reinforced by pharmaceutical companies, who note that the findings "underscore the chronic character of obesity," akin to managing conditions like diabetes.
User Testimonies
People who have stopped the medication explain a powerful return of hunger.
"I experienced a trigger flipping and you become starving," recalled an individual.
This challenge is exacerbated if patients have not adopted permanent lifestyle or habit changes during therapy.
Widespread Adoption
Survey data suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with demand remaining high.
- Use is more common among women than males.
- The middle-aged demographic shows the highest level of interest.
- A large proportion access the drugs through private healthcare rather than the NHS.
In conclusion, researchers emphasize that while these medications are effective agents for shedding pounds, they are not a standalone cure and maintained weight loss hinges on combined lifestyle changes.
